摘要
目的:探讨rhG-CSF预防性疗法对乳腺癌化疗骨髓抑制患者的影响。方法:选取120例接受治疗的乳腺癌患者作为研究对象。根据随机数字法将120例患者划分为试验组与常规组。两组患者在治疗之前均应用地塞米松、帕洛诺斯琼注射液进行治疗。试验组在化疗后48 h内给予患者注射重组人粒细胞集落刺激因子的治疗,100μg皮下注射,1次/d,连用3 d。常规组不注射rhG-CSF,只采取常规护理措施。统计并对比两组患者的血液指标以及不良反应。结果:化疗后,两组白细胞、中性粒细胞均下降,但试验组白细胞计数、中性粒细胞均显著优于常规组患者,上述两项数据差异突出,差异有统计学意义(P <0. 05);试验组患者的不良反应发生率为8. 33%,常规组患者的不良反应发生率为56. 67%,差异有统计学意义(P <0. 05)。结论:rhG-CSF预防性疗法对乳腺癌化疗骨髓抑制患者的影响突出,治疗效果更加理想并且不良反应发生率较低,疗效确切且安全,可以更好地优化患者的治疗体验,值得推广普及。
Objective To explore the effect of rhG-CSF preventive treatment on patients with bone marrow suppression after chemotherapy for breast cancer.Method 120 cases of breast cancer treated in our hospital were selected as subjects.According to the random number method,120 patients were divided into the experimental group and the conventional group.Both groups were treated with dexamethasone and paronosetron before treatment.In the experimental group,recombinant human granulocyte colony stimulating factor was injected into the patient within 48 hours after chemotherapy,100μg hypodermic injections were given,once per day,for 3 consecutive days.rhG-CSF was not injected into the routine group,and only routine nursing measures were taken.Blood parameters and adverse reactions were compared between the two groups.Results After chemotherapy,two groups of white blood cells,neutrophils decreased,but the experimental group of white blood cell count,neutrophils were significantly better than the conventional group of patients,the two data gap was outstanding,the results showed statistically significant(P<0.05);The incidence of adverse reactions in the experimental group was 8.33%and the incidence of adverse reactions in the conventional group was 56.67%,and the difference was statistically significant(P<0.05).Conclusion rhG-CSF preventive therapy for breast cancer chemotherapy patients with bone marrow suppression is outstanding,the influence of treatment effect is more ideal and a lower incidence of adverse reaction,curative effect and security,can optimize the treatment of patients with better experience,is worth popularizing.
作者
陈淑如
CHEN Shu-ru(Breast surgery,Huizhou central people's hospital,Huizhou 516000,China)
出处
《吉林医学》
CAS
2019年第1期68-70,共3页
Jilin Medical Journal
基金
惠州市科技计划项目[项目编号:2017Y013]
关键词
RHG-CSF
乳腺癌化疗
骨髓移植
临床影响
rhG-CSF
Chemotherapy for breast cancer
Bone marrow transplantation
Clinical effect